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Abstract 
The CTX-M type enzymes have become the most prevalent extended spectrum 
β-lactamases (ESBLs) worldwide.  Among the CTX-M type enzymes, CTX-M-15 is the 
most widespread and has been reported from all continents.  It has been recovered 
from different Enterobacteriaceae and has been isolated from both community and 
hospital acquired infections.  This review primarily highlights the prevalence of CTX-
M-15 in addition to other ESBLs in the Middle East.  Detection of any type of ESBL is 
of importance in therapeutic treatment. 
Keywords: CTX-M-15, ESBL, Middle East, antimicrobial resistance, Enterobacteria-
ceae.
Introduction
As is the case for many antimicrobial agents, over-use of the 
extended spectrum oxyimino-cephalosporins, which are 
agents developed to treat organisms producing β-lactamases, 
resulted in the production of enzymes capable of hydrolyzing 
these agents. In 1983, the first extended spectrum β lactamase, 
an SHV β-lactamase derivate, was isolated in Germany from a 
Klebsiella isolate (1,2).  Since then, the family of ESBLs has grown 
to include enzymes belonging to Ambler Classes A, including 
many derivates of plasmid mediated TEM and SHV penicilli-
naces, and a small number of Class D OXA-type β-lactamases 
(2,3).  A third type of Class A ESBLs, the cefotaximase, or CTX-M 
enzyme, was first identified from an Escherichia coli isolate in 
Germany in 1990 (4).  Unlike other ESBLs, this enzyme hydro-
lyzed cefotaxime more efficiently than ceftazidime, and in gen-
eral, CTX-M enzymes tend to confer resistance to cefotaxime 
but not to ceftazidime (4,5).
Outbreaks of organisms producing CTX-M type ESBLs were re-
ported from around the world as early as the 1990s, however, 
with a few exceptions, organisms expressing these enzymes 
were not identified in the Middle East till earlier this decade 
(2,5,6,7).  Over the past ten years, the CTX-M enzymes have 
become the most prevalent ESBLs among multidrug resistant 
organisms worldwide, especially in certain countries in Europe 
and South America (6,8,9,10).  As for the Middle East, there is lit-
tle data on the prevalence and distribution of these enzymes. 
These enzymes are of special importance because they have 
been isolated from both hospital and community-acquired iso-
lates, particularly Escherichia coli isolates causing urinary tract 
infections; and, also because of their clonal, plasmid-mediated 
nature (6,7,8). The majority of CTX-M type enzymes are associ-
ated with the insertion sequence ISEcp1 (9,11).  
A major enzyme among the CTX-M ESBLs is CTX-M-15, an 
enzyme that has been associated with epidemic and mosaic 
plasmids, and that may play a role in conferring carbapenem 
resistance when found in isolates showing outer membrane 
impermeabilities (3,9,12,13). Unlike other CTX-M enzymes, CTX-
M-15 efficiently hydrolyzes both cefotaxime and ceftazidime 
(14).  In addition CTX-M-15, encoded by the blaCTX-M-15 gene, 
is sometimes associated with other ESBLs encoding genes, 
such as blaTEM and blaSHV derivatives and blaOXA-1 as well as 
genes encoding for resistance to other antimicrobial agents, 
such as the qnrA and qnrB genes conferring resistance to fluo-
roquinolones, and aac(6’)-Ib-cr, conferring resistance to ami-
noglycosides and fluoroquinolones (15,16,17,18,19).  It was first 
detected in an E. coli isolate in India in 2001, but since then, it 
has become the most disseminated ESBL worldwide, mainly as 
a single clone ST131 O25:H4 (14,20).  It is the predominant CTX-
M enzyme in Europe, and in India, which may be considered 
a major reservoir for E. coli isolates harboring the blaCTX-M-15 
gene (6,20,21,22).  It has also been identified in E. coli isolates 
from North and South America, Asia, Australia, Africa and the 
Middle East (10,23-28).  
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Distribution of blaCTX-M-15 in the Middle East
Among the Middle Eastern countries, CTX-M-15 is most wide-
spread and is the predominant ESBL in Egypt, Kuwait, Leba-
non, and the United Arab Emirates; as for other countries in 
the region, distribution and prevalence varies or has not been 
reported yet (28-31).  
Egypt
High rates of ESBL production have been reported for Egypt 
since 2003, however, the presence of blaCTX-M-15 was not re-
ported until 2006, in a study conducted by Al-Agamy et al 
(29,32,33). Al-Agamy et al found that 25 of 28 ESBL producing 
E. coli isolates were carriers of CTX-M type enzymes, and that of 
these isolates, 13 harbored blaCTX-M-15 (29).  At the time, there 
was no information available on the spread of CTX-M enzymes 
in Egypt (29). Since then, a more thorough study conducted 
by Fam et al identified 74 isolates producing blaCTX-M-15, con-
stituting all ESBL producers that were available for molecular 
study (34).   
Iran
Feizabadi et al reported in 2006 a high prevalence of ESBL pro-
duction among K. pneumoniae isolates collected at two teach-
ing hospitals in Tehran, Iran (35).  A similar study conducted in 
2008 by Mehrgan et al reported that among the high number 
of ESBL producing E. coli isolates identified, some showed an 
antimicrobial resistance profile suggestive of the presence of 
a CTX-M type enzyme, but molecular data was lacking (36).  
In 2009, Ramazanzadeh et al studied the spread of ESBLs in In-
tensive Care Units in two major hospitals in Sanandaj and found 
that the most prevalent ESBL belonged to the CTX-M family, 
but the types of CTX-M enzymes present were not determined 
(37).  Following in 2010, Feizabadi et al reported the presence 
of the blaCTX-M-15 gene in a high number of ESBL producing 
K. pneumoniae isolates among those tested (38).  Later studies 
conducted by Feizabadi et al showed an increase in the CTX-
M phenotype among ESBL producing K. pneumoniae isolates 
collected from hospitalized patients (39).  In Iran, CTX-M-15 
has also been identified among different Salmonella enterica 
serovars and among non-typhoidal Salmonella strains (40,41).
Iraq
ESBL production has been reported in Iraq, however, molecular 
data is scarce in the country (42).  Reports of Iraqi isolates pro-
ducing the CTX-M-15 enzyme come from studies conducted in 
France and Germany (43,44).  In both cases, the isolates were 
transferred to these respective countries by patients from Iraq 
(43,44).  In France, the CTX-M-15 enzyme was associated with 
blaNDM-1 production in a K. pneumoniae isolate (43).  In Ger-
many, the CTX-M-15 enzyme was isolated from a Salmonella 
enterica serovar Typhi (44).  This data suggests that CTX-M-15 
may be prevalent in Iraq.
Kuwait
Two studies from 2008 identifying the E. coli ST131 clone pro-
ducing CTX-M-15 in a number of countries worldwide also 
identified this clone in Kuwait (45,46).   Also in 2008, Rotimi et al 
reported for the first time in Kuwait, and in the gulf region, an 
outbreak of Salmonella spp producing CTX-M-15 (47). In 2009, 
Ensor et al tried to identify the prevalence of CTX-M enzymes 
in Kuwait by randomly selecting 43 ESBL producing E. coli and 
K. pneumoniae isolates collected at the Mubarak hospital and 
found that among these isolates, CTX-M-15 was the predomi-
nant enzyme (30).  In 2010 and 2011, CTX-M-15 was identified 
from Klebsiella pneumoniae isolates in a number of studies, and 
a CTX-M-15-like enzyme clone was identified from an outbreak 
occurring in a neonatal intensive care unit at Al Jahra hospital 
(48,49).  The K. pneumoniae isolate identified at the Al Jahra 
hospital also carried blaTEM-1 and blaSHV-112 genes (49).  
In 2010, Al Hashem et al attempted to investigate the extent 
and distribution of blaCTX-M genes among E. coli isolates from 
all government hospitals in Kuwait.  Isolates were collected 
from eight major hospitals in Kuwait and 136 ESBL producers 
were identified.  The most prevalent enzyme among the ESBL 
producers, with a prevalence of 84.1%, was CTX-M-15, suggest-
ing that Kuwait may be an important source for CTX-M-15 pro-
ducing E. coli isolates (50).
Lebanon
In Lebanon, there is a countrywide dissemination of the blaCTX-
M-15 gene (28).  CTX-M-15 has been identified in many mem-
bers of the Enterobacteriaceae from both community and hos-
pital acquired infections (28,51,52,53). In a nationwide study 
conducted in 2005 that included six tertiary care centers in 
Lebanon, Moubareck et al identified CTX-M-15 from E. coli, 
Klebsiella pneumoniae, and Enterobacter cloaceae isolates (28). 
That same year, Moubareck et al identified the first Salmonella 
enterica serovar Typhimurium isolate producing CTX-M-15 in 
the country, reporting for the first time in Lebanon an ESBL 
producing Salmonella isolate (53).  Subsequently, Kanj et al re-
ported a high prevalence of CTX-M-15 production in E. coli and 
K. pneumoniae isolates from a tertiary care center in Lebanon 
and Matar et al reported CTX-M-15 from two Salmonella en-
terica serovar Typhimurium isolates and three Shigella sonnei 
isolates, making CTX-M-15 the predominant ESBL identified in 
the country (51,52, 54,55). 
Oman
Studies conducted in Oman on isolates collected from pediat-
ric patients, intensive care unit and other hospitalized patients 
and from outpatient clinics suggest an increasing prevalence 
of ESBL producers, however, these studies did not attempt to 
identify the types of ESBL genes present (56,57,58). In a review 
on susceptibilities of common bacterial isolates collected from 
the Royal Hospital in Oman, resistance to third generation 
cephalosporins varied among the Enterobacteriaceae, and, as 
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mentioned by the authors, was possibly due to CTX-M type 
enzymes, which had been detected at the center previously 
(59). The only report of an isolate producing CTX-M-15 com-
ing from Oman is from a K. pneumoniae isolate also harboring 
blaNDM-1 (60).    
Saudi Arabia
Al Agamy et al identified the first CTX-M enzymes from Saudi 
Arabia in 2009 in a study they conducted to determine the 
prevalence of ESBLs among K. pneumoniae isolates in Riyadh 
(61).  Prevalent among these enzymes were blaCTX-M-15 like 
genes belonging to the CTX-M-1 group (61).  Furthermore, 
Bindayna et al reported in 2010 that the most prevalent ESBL 
among 100 isolates collected in Dhahran was CTX-M, how-
ever, in this study the specific type of CTX-M enzyme present 
was not determined (62).  In 2011, Tawfik et al reported a high 
prevalence of CTX-M-15 among 110 ESBL producing clinical K. 
pneumoniae isolates collected in Al-Qassim (63).  
Turkey
In 2003, Lartigue et al reported the first clinical isolate, a Kleb-
siella pneumoniae, producing CTX-M-15 in Turkey (64).  In 2007, 
Yildirim et al reported a Klebsiella pneumoniae isolate that 
produced blaCTX-M-15 as well as a carbapenemase (65).  Fol-
lowing in 2008, a study conducted at a university hospital in 
Istanbul by Gonullu et al revealed a high prevalence of CTX-
M-15 among E. coli isolates recovered from inpatients and out-
patients treated at the center (66). Similarly, between 2008 and 
2010, studies to determine the prevalence of CTX-M-15 produc-
tion in E. coli isolates from community acquired infections re-
ported that the prevalence of CTX-M-15 was quite high among 
those isolates producing ESBLs (67,68,69).  
United Arab Emirates
In a first report of the production of CTX-M-type enzymes in 
the Arabian Peninsula, five entero-aggregative E. coli isolates 
from the United Arab Emirates were found to harbor blaCTX-
M-15 and blaTEM-1 (31).  CTX-M-15 was then identified in a sin-
gle Salmonella group C isolate in the 2008 study conducted 
by Rotimi et al mentioned previously (47). In 2011, in a study 
collecting ESBL producing isolates from hospitalized patients 
in three hospitals across the UAE, the majority of the isolates 
among those identified as ESBL producers harbored blaCTX-
M-15 (70).  
Others
In the Gaza Strip, Jordan, and Bahrain, resistance data suggests 
the production of extended spectrum β-lactamases but to date 
no studies have attempted to identify and characterize the ge-
netic determinants causing this ESBL phenotype (33,71,72).  In 
one study from Jordan, Shehabi et al observed a high rate of 
Klebsiella pneumoniae isolates resistant to extended spectrum 
cephalosporins among ICU patients, suggesting that these 
isolates were potentially ESBL producers; extended spectrum 
cephalosporin resistance was also observed among E. coli and 
Enterobacter spp isolates, but at a lower rate (74).  Though there 
have been no reports of CTX-M-15 throughout the rest of Pal-
estine, other CTX-M enzymes, especially CTX-M-2, have been 
identified from E. coli isolates (75).  No data has been published 
on ESBLs for Yemen, Qatar and Syria.
Conclusion
Data from the Middle East shows that CTX-M-15 is prevalent in 
more than one country, and that the encoding gene is many 
times associated with other resistance encoding genes, includ-
ing other ESBLs (31,38,51).  This is not surprising as in many 
countries in the Middle East antimicrobials can be purchased 
without a prescription and are commonly misused, possibly 
resulting in the selection of antimicrobial resistant strains 
(29,36,50).  In Kuwait, a number of studies attributed part of 
the high prevalence of CTX-M-15 to a large population of non-
nationals; this could also be the case for other countries in the 
gulf region, where many non-nationals also live (30,50).  
Since the ST131 clone carrying CTX-M-15 was identified in Ku-
wait, Multi-Locus Sequence Typing may shed light on whether 
the same clone is prevalent in other countries in the Middle 
East (45,46).  Similar to reports from other countries, CTX-M-15 
was identified from both hospital and community acquired 
infections and in a number of members of the Enterobacteria-
ceae, including E. coli, K. pneumoniae, and Salmonella spp (6,9). 
In many instances, the blaCTX-M-15 gene was found to be en-
coded by an ISEcp1 insertion sequence, as reported elsewhere 
(31,47, 51-53,64).  
Finally, though some countries in the Middle East have re-
ported molecular data on the types of ESBLs present, many 
countries fail to routinely identify ESBls and lack data on the 
prevalence of isolates producing these enzymes at the nation-
al level.  The high prevalence of ESBL production among all 
types of Enterobacteriaceae reported from a number of coun-
tries implies that there is an urgent need for regular screening 
for extended spectrum β-lactamases production, in order to 
identify such genes as CTX-M-15, but also others.  Determin-
ing the presence of an ESBL and then identifying its type is 
important for prescribing proper antimicrobial treatment and 
for avoiding therapeutic failure or an unwanted clinical out-
come (37,75,76,77).  
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